


Summary

In one aspect, there is provided a compound of formula I,



wherein

5 X¹ is C-R¹ or N;

X² is C-R¹ or N;

X³ is C-R¹ or N;

X⁴ is C-R¹ or N;

whereby only one of X¹, X², X³ and X⁴ is N;

10 R¹ each separately is selected from the group consisting of hydrogen, halogen, hydroxy, C₁-₆-alkyl and C₁-₆-alkoxy;

R² is selected from the group consisting of H and C₁-₆-alkyl;

R³ is selected from the group consisting of H and C₁-₆-alkyl;

or R² and R³ together are =O;

15 Y¹ is C-R⁴ or N;

Y² is C-R⁴ or N;

Y³ is C-R⁴ or N;

Y⁴ is C-R⁴ or N;

whereby only one of Y¹, Y², Y³ and Y⁴ is N;

20 R⁴ each separately is selected from the group consisting of hydrogen, halogen, halogen-C₁-₆-alkyl, hydroxy, C₁-₆-alkyl, C₁-₆-alkoxy and Si(C₁-₆-alkyl)₃;

m is 1, 2 or 3; and

n is 0 or 1;

or pharmaceutically acceptable salts thereof.

In another aspect, there is provided an intermediate of a compound of formula I as defined herein, wherein,

5 X¹ is C-R¹;

X² is C-R¹;

X³ is C-R¹;

X⁴ is NO;

10 R¹ each separately is selected from the group consisting of hydrogen, halogen, hydroxy, C₁₋₆-alkyl and C₁₋₆-alkoxy;

R² is selected from the group consisting of H and C₁₋₆-alkyl;

R³ is selected from the group consisting of H and C₁₋₆-alkyl;

or R² and R³ together are =O;

Y¹ is C-R⁴ or N;

15 Y² is C-R⁴ or N;

Y³ is C-R⁴ or N;

Y⁴ is C-R⁴ or N;

whereby only one of Y¹, Y², Y³ and Y⁴ is N;


20 R⁴ each separately is selected from the group consisting of hydrogen, halogen, halogen-C₁₋₆-alkyl, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy and Si(C₁₋₆-alkyl)₃;

m is 1, 2 or 3; and


n is 0 or 1;

or pharmaceutically acceptable salts thereof.

In another aspect, there is provided a process to manufacture a compound of formula I, comprising the step of reacting a compound of formula (II)



with a compound of formula (III)



wherein n, m, R², R³, X¹⁻⁴ and Y¹⁻⁴ are as defined hereinabove for formula (I).

In another aspect, there is provided a compound of formula I as defined herein, whenever prepared by a process as defined herein.


In another aspect, there is provided a compound of formula I as defined herein for use as therapeutically active substance.

In another aspect, there is provided a compound of formula I as defined herein for the use as therapeutically active substance acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

In another aspect, there is provided a pharmaceutical composition comprising a compound of formula I as defined herein and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.

In another aspect, there is provided use of a compound of formula I as defined herein for the manufacture of a medicament for acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive

disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.



wherein n, m, R², R³, X¹⁻⁴ and Y¹⁻⁴ are as defined hereinabove for formula (I).

14. A compound of formula I according to any of claims 1 to 12, whenever prepared by a process as defined in claim 7.

15. A compound of formula I according to any of claims 1 to 12 for use as therapeutically active substance.

16. A compound of formula I according to claims 1 to 12 for the use as therapeutically active substance acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

17. A pharmaceutical composition comprising a compound of formula I according to any of claims 1 to 12 and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.

18. Use of a compound of formula I according to any of claims 1 to 12 for the manufacture of a medicament for acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

~~19. A method for the use of a compound according to any of claims 1 to 12 acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag, which method comprises administering said compound of formula I to a human being or animal.~~